Barclays
VOR icon

Barclays’s Vor Biopharma VOR Stock Holding History

Barclays’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.43K Sell
136
-1,263
-90% -$17.8K ﹤0.01% 4835
2025
Q4 		$18.3K Buy
+1,399
New +$26.1K ﹤0.01% 4879
2025
Q2 		– Sell
-4,987
Closed -$71.6K – 5558
2025
Q1 		$71.6K Buy
4,987
+4,436
+805% +$107K ﹤0.01% 4511
2024
Q4 		$12.2K Hold
551
– – ﹤0.01% 4973
2024
Q3 		$7.72K Sell
551
-737
-57% -$13.4K ﹤0.01% 4997
2024
Q2 		$25.8K Sell
1,288
-636
-33% -$20.6K ﹤0.01% 4393
2024
Q1 		$91.2K Sell
1,924
-680
-26% -$29.9K ﹤0.01% 4463
2023
Q4 		$117K Buy
2,604
+2,243
+621% +$92.6K ﹤0.01% 4602
2023
Q3 		$15.3K Sell
361
-17
-4% -$922 ﹤0.01% 4228
2023
Q2 		$23.3K Buy
+378
New +$34.5K ﹤0.01% 4105
2022
Q2 		– Sell
-154
Closed -$19K – 5287
2022
Q1 		$19K Buy
+154
New +$26.2K ﹤0.01% 4465

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's VOR Position: Q1 2026 in Review

Barclays reduced its Vor Biopharma (VOR) stake by 90% in Q1 2026, selling an estimated $17.8K and leaving 136 shares worth $2.43K. The position accounts for ﹤0.01% of the portfolio, ranked #4835.

Barclays first reported a position in VOR in Q1 2022 and has held it in 11 quarters since. The position peaked at $117K in Q4 2023. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Barclays held 136 shares of Vor Biopharma worth $2.43K as of Q1 2026.
  • Barclays sold 1,263 Vor Biopharma shares in Q1 2026, an estimated $17.8K.
  • Vor Biopharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4835 holding.
  • Barclays first reported a position in Vor Biopharma in Q1 2022 and has held it in 11 quarters since.
  • Barclays's Vor Biopharma position peaked at $117K in Q4 2023.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.